Case report: immune response characterization of a pseudoprogression in a pd-l1-negative, tmb-low, keap1/stk11 co-mutated metastatic nsclc

HIGHLIGHTS

• What: The authors report the first case of a pseudoprogression with durable complete response that occurred spontaneously after an unequivocal progression under a standard chemoimmunotherapy regimen in a patient with a PD-L1-negative, TMB-low, KEAP1/ STK11 co-mutated NSCLC. The authors demonstrate a specific T-cell response against CD8-restricted Frontiers in Immunology Patient perspective From the patient perspective, performance status was not altered at the time of pseudoprogression.
• Who: NSCLC et al. from the Medical University of Innsbruck, Austria have published the research work: Case report: Immune response characterization of a pseudoprogression . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.